Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Drug Discovery Services Market 

5.1. COVID-19 Landscape: Drug Discovery Services Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Drug Discovery Services Market, By Process

8.1. Drug Discovery Services Market, by Process Type, 2023-2032

8.1.1. Target Selection

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Target Validation

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Hit to Lead Identification

8.1.3.1. Market Revenue and Forecast (2020-2032)

8.1.4. Lead Optimization

8.1.4.1. Market Revenue and Forecast (2020-2032)

8.1.5. Candidate Validation

8.1.5.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Drug Discovery Services Market, By Drug Type

9.1. Drug Discovery Services Market, by Drug Type, 2023-2032

9.1.1. Small Molecules

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Biologics

9.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Drug Discovery Services Market, By Type

10.1. Drug Discovery Services Market, by Type, 2023-2032

10.1.1. DMPK

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Biology Services

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Medicinal Chemistry

10.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Drug Discovery Services Market, By Therapeutic Area

11.1. Drug Discovery Services Market, by Therapeutic Area Type, 2023-2032

11.1.1. Oncology

11.1.1.1. Market Revenue and Forecast (2020-2032)

11.1.2. Cardiovascular Diseases

11.1.2.1. Market Revenue and Forecast (2020-2032)

11.1.3. Diabetes

11.1.3.1. Market Revenue and Forecast (2020-2032)

11.1.4. Neurology

11.1.4.1. Market Revenue and Forecast (2020-2032)

11.1.5. Respiratory Diseases

11.1.5.1. Market Revenue and Forecast (2020-2032)

11.1.6. Others

11.1.6.1. Market Revenue and Forecast (2020-2032)

Chapter 12. Global Drug Discovery Services Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Process (2020-2032)

12.1.2. Market Revenue and Forecast, by Drug Type (2020-2032)

12.1.3. Market Revenue and Forecast, by Type (2020-2032)

12.1.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Process (2020-2032)

12.1.5.2. Market Revenue and Forecast, by Drug Type (2020-2032)

12.1.5.3. Market Revenue and Forecast, by Type (2020-2032)

12.1.5.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Process (2020-2032)

12.1.6.2. Market Revenue and Forecast, by Drug Type (2020-2032)

12.1.6.3. Market Revenue and Forecast, by Type (2020-2032)

12.1.6.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Process (2020-2032)

12.2.2. Market Revenue and Forecast, by Drug Type (2020-2032)

12.2.3. Market Revenue and Forecast, by Type (2020-2032)

12.2.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Process (2020-2032)

12.2.5.2. Market Revenue and Forecast, by Drug Type (2020-2032)

12.2.5.3. Market Revenue and Forecast, by Type (2020-2032)

12.2.5.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Process (2020-2032)

12.2.6.2. Market Revenue and Forecast, by Drug Type (2020-2032)

12.2.6.3. Market Revenue and Forecast, by Type (2020-2032)

12.2.6.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Process (2020-2032)

12.2.7.2. Market Revenue and Forecast, by Drug Type (2020-2032)

12.2.7.3. Market Revenue and Forecast, by Type (2020-2032)

12.2.7.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Process (2020-2032)

12.2.8.2. Market Revenue and Forecast, by Drug Type (2020-2032)

12.2.8.3. Market Revenue and Forecast, by Type (2020-2032)

12.2.8.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Process (2020-2032)

12.3.2. Market Revenue and Forecast, by Drug Type (2020-2032)

12.3.3. Market Revenue and Forecast, by Type (2020-2032)

12.3.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Process (2020-2032)

12.3.5.2. Market Revenue and Forecast, by Drug Type (2020-2032)

12.3.5.3. Market Revenue and Forecast, by Type (2020-2032)

12.3.5.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Process (2020-2032)

12.3.6.2. Market Revenue and Forecast, by Drug Type (2020-2032)

12.3.6.3. Market Revenue and Forecast, by Type (2020-2032)

12.3.6.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Process (2020-2032)

12.3.7.2. Market Revenue and Forecast, by Drug Type (2020-2032)

12.3.7.3. Market Revenue and Forecast, by Type (2020-2032)

12.3.7.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Process (2020-2032)

12.3.8.2. Market Revenue and Forecast, by Drug Type (2020-2032)

12.3.8.3. Market Revenue and Forecast, by Type (2020-2032)

12.3.8.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Process (2020-2032)

12.4.2. Market Revenue and Forecast, by Drug Type (2020-2032)

12.4.3. Market Revenue and Forecast, by Type (2020-2032)

12.4.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Process (2020-2032)

12.4.5.2. Market Revenue and Forecast, by Drug Type (2020-2032)

12.4.5.3. Market Revenue and Forecast, by Type (2020-2032)

12.4.5.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Process (2020-2032)

12.4.6.2. Market Revenue and Forecast, by Drug Type (2020-2032)

12.4.6.3. Market Revenue and Forecast, by Type (2020-2032)

12.4.6.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Process (2020-2032)

12.4.7.2. Market Revenue and Forecast, by Drug Type (2020-2032)

12.4.7.3. Market Revenue and Forecast, by Type (2020-2032)

12.4.7.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Process (2020-2032)

12.4.8.2. Market Revenue and Forecast, by Drug Type (2020-2032)

12.4.8.3. Market Revenue and Forecast, by Type (2020-2032)

12.4.8.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Process (2020-2032)

12.5.2. Market Revenue and Forecast, by Drug Type (2020-2032)

12.5.3. Market Revenue and Forecast, by Type (2020-2032)

12.5.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Process (2020-2032)

12.5.5.2. Market Revenue and Forecast, by Drug Type (2020-2032)

12.5.5.3. Market Revenue and Forecast, by Type (2020-2032)

12.5.5.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Process (2020-2032)

12.5.6.2. Market Revenue and Forecast, by Drug Type (2020-2032)

12.5.6.3. Market Revenue and Forecast, by Type (2020-2032)

12.5.6.4. Market Revenue and Forecast, by Therapeutic Area Type (2020-2032)

Chapter 13. Company Profiles

13.1. Abbott Laboratories Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Advinus Therapeutics

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Agilent Technologies Ubiquigent

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Albany Molecular Research Inc.

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. AstraZeneca PLC

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Aurigene

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Bayer AG

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Charles River Laboratories International

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. ChemBridge Corporation

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Covance

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms